• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

‘Body-on-a-chip’ device screens human heart cells for drug toxicity

August 25, 2017 By Sarah Faulkner

body-on-a-chip deviceResearchers at Kyoto University‘s Institute for Integrated Cell-Material Sciences have developed a ‘body-on-a-chip’ device that can evaluate the side-effects of drugs on human cells, according to a study published today in the Royal Society of Chemistry Advances.

The device was used to test the toxicity of doxorubicin, a cancer-killing drug, on human heart cells. The researchers found that although the drug wasn’t toxic to the cells, a metabolite of the drug was.

The ‘body-on-a-chip’ device, which is smaller than a microscope slide, has six small chambers that are connected by microchannels with a series of inlets and valves. A pump controls the movement of fluid through the channels. Every two chambers and their microchannel system makes up one test bed, the team reported.

The researchers tested doxorubicin’s effects on healthy heart cells and liver cancer cells cultured separately in small wells. The drug acted as expected with the cancer cells and did not cause damage to the heart cells.

Then, the team ran the same test using their device, with heart cells in one chamber and liver cancer cells in the other chamber. The researchers introduced doxorubicin into a cell culture circulating through a system of microchannels that connected the two chambers, allowing the drug to flow in one direction in a loop through both chambers.

They observed that the drug produced toxic side effects in both heart and cancer cells. On a hunch that a metabolic byproduct of doxorubicin, doxorubicinol, was producing the toxic effect, they added it to heart cells and liver cancer cells separately.

The doxorubicinol was toxic to the heart cells but not to the cancer cells.

When doxorubicin was added to the team’s device, the metabolite was not diluted while moving through the microchannel circulation system since a smaller volume of cell culture was needed compared to their first experiment, the team reported. This created the drug’s toxic side effect.

The study is demonstrative of how the device could be used to investigate a drug’s potential side effects before launching expensive clinical trials, according to the researchers.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Oncology, Pharmaceuticals, Research & Development Tagged With: Kyoto University

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS